Valuation: Wockhardt Limited

Market Cap 300B 3.12B 2.74B 2.55B 2.34B 4.39B 4.46B 30.26B 11.82B 148B 11.71B 11.46B 511B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 316B 3.28B 2.88B 2.68B 2.46B 4.62B 4.69B 31.83B 12.43B 155B 12.32B 12.05B 537B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-0.03%
1 week-2.71%
Current month-4.75%
1 month-6.05%
3 months+31.60%
6 months+36.82%
Current year+27.87%
1 week 1,825.7
Extreme 1825.7
1,950
1 month 1,792.4
Extreme 1792.4
1,994
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.03%-2.71%+8.69%+669.54% 3.12B
-0.66%+0.44%+14.72%+76.40% 48.36B
+2.20%+1.41%+61.04%+111.43% 35.8B
+1.26%-0.57%-5.20%+34.48% 11.83B
-0.46%-3.06%+14.15%+80.63% 11.48B
-0.37%-0.37%+37.89%+137.78% 9.01B
+1.52%+0.39%+48.79%-5.82% 6.99B
-0.17%-2.92%+13.13%+30.45% 6.7B
-0.59%-1.95%+2.23%+178.07% 6.42B
-7.92%-13.61%-34.97%-4.08% 5.3B
Average -0.52%-2.18%+16.05%+130.89% 14.5B
Weighted average by Cap. +0.12%-0.50%+24.99%+94.01%

Financials

2025 2026
Net sales 30.35B 315M 277M 257M 236M 444M 451M 3.06B 1.19B 14.92B 1.18B 1.16B 51.59B 34.62B 359M 316M 294M 269M 506M 514M 3.49B 1.36B 17.02B 1.35B 1.32B 58.85B
Net income -470M -4.88M -4.29M -3.99M -3.66M -6.87M -6.98M -47.34M -18.49M -231M -18.32M -17.93M -799M 2.13B 22.12M 19.43M 18.07M 16.58M 31.15M 31.63M 215M 83.81M 1.05B 83.03M 81.24M 3.62B
Net Debt 14.33B 149M 131M 122M 112M 210M 213M 1.44B 564M 7.05B 559M 547M 24.36B 15.53B 161M 142M 132M 121M 227M 231M 1.56B 611M 7.64B 605M 592M 26.4B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-07-24 ₹1,849.20 -0.03% 330,095
26-07-23 ₹1,849.70 -0.63% 498,914
26-07-22 ₹1,861.50 -1.84% 801,530
26-07-21 ₹1,896.30 -1.41% 296,564
26-07-20 ₹1,923.40 +1.19% 959,200
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock